Changing the paradigm for treatment intensification; combination therapy in type 2 diabetes (T2D)
The clinical benefits of IDegLira in DUAL VII™ were achieved while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy.
This session will include:
- The definition and need for insulin intensification in patients with T2D
- The complementing benefits of insulin and GLP1-RA therapy in patients with T2D
- The available clinical evidence for Xultophy® (100 U/ml Insulin Degludec + 3.6 mg/ml Liraglutide), combination therapy in type 2 diabetes, and practical consideration for clinical use
Xultophy® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes.
Date of Prep: October 2019 (UK19OZM00262)
*This is a promotional symposium organised and funded by Novo Nordisk. Prescribing information for all relevant products will be made available during the meeting
Tuesday 29 October 2019
11:00 - 11:20